{"pub_date": "2016-03-16T00:00:00Z", "subsection_name": null, "lead_paragraph": "As Valeant Pharmaceuticals\u2019 market value sinks, the company\u2019s future may hinge on what it can get now for the companies it bought.", "print_page": "1", "document_type": "article", "byline": {"person": [{"rank": 1, "organization": "", "lastname": "MORGENSON", "firstname": "Gretchen", "role": "reported"}], "original": "By GRETCHEN MORGENSON"}, "multimedia": [], "section_name": "Business Day", "headline": {"content_kicker": "Fair Game", "print_headline": "Figuring Valeant\u2019s True Value", "main": "Figuring Out What Valeant Is Really Worth", "kicker": "Fair Game"}, "source": "The New York Times", "blog": [], "word_count": "859", "web_url": "http://www.nytimes.com/2016/03/16/business/figuring-out-what-valeant-is-really-worth.html", "slideshow_credits": null, "news_desk": "Business", "type_of_material": "An Analysis; News Analysis", "snippet": "As Valeant Pharmaceuticals\u2019 market value sinks, the company\u2019s future may hinge on what it can get now for the companies it bought.", "_id": "56e892eb38f0d85c820e6404", "abstract": "Gretchen Morgenson Fair Game column addresses question of how to determine worth of Valeant Pharmaceuticals, in light of steep drop in company's shares; notes analysts have doubts about company's ability to raise cash, despite Pershing Square Capital Management William A Ackman's assurances.", "keywords": [{"rank": "1", "name": "organizations", "value": "Valeant Pharmaceuticals International Inc", "is_major": "Y"}, {"rank": "2", "name": "organizations", "value": "Pershing Square Capital Management", "is_major": "Y"}, {"rank": "3", "name": "persons", "value": "Ackman, William A", "is_major": "Y"}, {"rank": "4", "name": "subject", "value": "Company Reports", "is_major": "N"}]}